Cargando…
Pharmacological Chaperone Therapy for Pompe Disease
Pompe disease (PD), a lysosomal storage disease, is caused by mutations of the GAA gene, inducing deficiency in the acid alpha-glucosidase (GAA). This enzymatic impairment causes glycogen burden in lysosomes and triggers cell malfunctions, especially in cardiac, smooth and skeletal muscle cells and...
Autores principales: | Borie-Guichot, Marc, Tran, My Lan, Génisson, Yves, Ballereau, Stéphanie, Dehoux, Cécile |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8659197/ https://www.ncbi.nlm.nih.gov/pubmed/34885805 http://dx.doi.org/10.3390/molecules26237223 |
Ejemplares similares
-
Second-Generation Pharmacological Chaperones: Beyond Inhibitors
por: Tran, My Lan, et al.
Publicado: (2020) -
The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease Fibroblasts
por: Porto, Caterina, et al.
Publicado: (2009) -
Pharmacological chaperone therapy for Fabry disease
por: ISHII, Satoshi
Publicado: (2012) -
Fragment-Based Ligand Discovery Applied to the Mycolic Acid Methyltransferase Hma (MmaA4) from Mycobacterium tuberculosis: A Crystallographic and Molecular Modelling Study
por: Galy, Romain, et al.
Publicado: (2021) -
Gene Therapy Developments for Pompe Disease
por: Unnisa, Zeenath, et al.
Publicado: (2022)